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The 64K surface protein of budded Autographa celifornica nuclear polyhedrosis virus (AcMNPV BV) is known to play 
a role in the functional entry of AcMNPV BV into Spodoptera ffugipefda IPLB-SF-21 cells by adsorptive endocytosis. 
AcV,, a neutralizing monoclonal antibody, reacts with the 64K protein and in doing so prevents efficient entry. In this 
communication we report that treatment of AcMNPV BV with either trypsin or proteinase K cleaves the 64K protein 
into one major fragment of 34.6K and two minor fragments of 36K to 37.2K that are retained with the virus. All of the 
fragments are glycosylated. Protease treatment does not reduce viral infectivity, but it does result in the destruction 
of the AcV,-reactive epitope; thus AcV, is not able to neutralize protease-treated AcMNPV BV. Polyclonal antiserum 
to BV is able to recognize both cleaved and uncleaved 64K and neutralize both protease-treated and untreated virus. 
Protease treatment does not diminish the sensitivity of AcMNPV BV to chloroquine, but it does cause the virus to 
become more susceptible to inactivation by 2-mercaptoethanol(2-ME) even though exposure to 2-ME does not result 
in dissociation of the fragments from the virus. 0 19SSAcademic PWSS. Inc. 
Autographa californica nuclear polyhedrosis virus 
(AcMNPV) is a member of subgroup A of the family Ba- 
culoviridae (9). Baculoviruses are restricted to arthro- 
pod hosts, and most infect lepidopteran insects. Bacu- 
loviruses of subgroups A and B have a unique survival 
strategy in that they use two phenotypes to complete 
an infection cycle in nature. One phenotype, made en- 
vironmentally stable by its inclusion within a crystalline 
proteinic matrix, initiates infection in midgut cells after 
being ingested by a susceptible insect host. The other 
phenotype amplifies the infection systemically, and 
matures by budding from the plasma membrane of in- 
fected cells as enveloped single nucleocapsids. The 
budded virus (BV) differs from the occluded virus in 
many ways (75). One significant difference is that BV 
has a major surface antigen, a phosphoglycoprotein of 
64,000 mol wt (64K) that functions in the efficient entry 
of BV by adsorptive endocytosis (17, 18). This protein 
is largely, if not totally, responsible for the significantly 
greater efficiency of infection of BV relative to the oc- 
cluded form both in the insect hemocoel and in cell cul- 
ture (6, 74). 
In this study, we document the effects of trypsin and 
proteinase K on 64K of AcMNPV BV and compare pro- 
tease-treated and untreated virus with regard to 
changes in infectivity after exposure to various biologi- 
cal and chemical reagents. 
The cell lines used in this study, IPLB-SF-21 and TN- 
368, were derived from Spodoprera frugiperde and Tri- 
’ To whom requests for reprints should be addressed. 
chop/Ma ni, respectively (16). The TN-368 cells were 
grown in TNM-FH medium (5), and the IPLB-SF-21 
cells were grown in TC-100 medium (4). The infectivity 
assay was the peroxidase antiperoxidase immunoas- 
say described previously (16) with an incubation time of 
40 hr, using IPLB-SF-21 cells unless specifically stated 
otherwise. BV was labeled with [35S]methionine and 
harvested as reported previously (18). Routine prote- 
ase treatment of BV consisted of incubation in 1 mg/ml 
proteinase K for 40 min at 4’ or 1 mg/ml trypsin for 40 
min at 27”, both in 0.05 M phosphate-buffered saline 
(PBS), pH 7.2, followed by addition of phenylmethylsul- 
fonyl fluoride (PMSF) to 0.004 11/1 and aprotinin to 2%. 
Protease-treated virus was then pelleted by centrifuga- 
tion (50,000 g for 1 hr) through a 25% sucrose cushion 
and resuspended in PBS containing 0.002 M PMSF 
and 1% aprotinin. In order to visualize the 64K protein 
and its cleavage fragments clearly, radiolabeled virus 
was mixed with solubilization buffer (PBS containing 
0.5% Nonidet-P40, 0.877% B-D octylglucoside, 1% 
aprotinin, and 0.002 M PMSF) at 27” overnight and pel- 
leted by centrifugation at 50,000 g for 1 hr. The super- 
nate of these samples was considered the soluble frac- 
tion and contained most of the 64K protein (or its cleav- 
age fragments), and the pellet was considered the 
particulate fraction. These samples were analyzed by 
SDS-PAGE and autoradiography (18). 
The effects of protease treatment on BV structural 
proteins are shown in Fig. 1. Analysis of the SDS- 
PAGE migration patterns of solubilized proteins, the 
nonsolubilized pelleted proteins, and the nonsolubi- 
285 0042-6822/88 $3.00 
Copyright Q 1988 by Academic Press, Inc. 
All rights of reproduction in any form reserved. 
286 SHORT COMMUNICATIONS 
sv TREAlMENrs 
Mr PBS TRYFSN FUOlENASEK Mr 
64K- 
SPWME SPWME SPWME 
FIG. 1. Effect of protease treatment and exposure to 4% 2-ME on 
BV structural proteins. [36S]methionine-labeled BV, treated with PBS 
alone or PBS containing trypsin or proteinase K, was pelleted through 
a 25% sucrose cushion, resuspended in PBS, and then analyzed by 
SDS-PAGE/autoradiography. Soluble (S) and particulate (P) frac- 
tions, as well as whole virus (W), were analyzed. Samples of pro- 
tease-treated and untreated whole virus were additionally incubated 
with 4% Z-ME at 37Ofor 15 min before analysis (ME). 
lized virus reveals that only the 64K protein appeared 
to be cleaved by the protease treatments. The major 
cleavage product of both proteinase K and trypsin was 
a fragment of estimated mol wt 34.6K. The molecular 
weights of the minor tryptic products were estimated 
to be 36K and 36.7K, while the minor proteinase K 
products were 36.7K and 37.2K. It is interesting that 
trypsin and proteinase K, quite different in their cleav- 
age site specificities (7, L?), cleaved 64K into such sim- 
ilar patterns. Surprisingly, the infectivity of protease- 
treated BV was not significantly altered from that of the 
starting BV preparation, as assessed both by plaque 
assay in cell culture and by intrahemocoelic injection 
into mid-fourth instar T. ni larvae (6), suggesting that 
the cleavage fragments of 64K retained by the virus af- 
ter protease treatment contained the biologically active 
portions of the protein (data not shown). 
It is known that the 64K protein of BV is a glycopro- 
tein (18). To determine which of the protease-gener- 
ated cleavage fragments were glycosylated we labeled 
BV with N-acetyl-D-[1-3-H]glucosamine as described 
before and treated it with protease, and examined the 
soluble fraction by SDS-PAGE and autoradiography. 
Figure 2 shows that for both trypsin and proteinase K- 
treated BV, all the fragments were glycosylated. It is 
probable that the carbohydrate moiety of the fragments 
protests them somewhat from proteolytic degradation, 
which would explain the similarity of the fragment pat- 
terns generated by the two different proteases. 
BV and protease-treated BV were exposed to various 
concentrations of 2-mercaptoethanol (2-ME) to deter- 
mine the effect on infectivity. These experiments were 
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FIG. 2. Protease cleavage of N-acetyl-o-[l-3H]glucosamine-labeled 
64K. N-acetyl-o-[1 -3H]glucosamine-labeled BV was treated with PBS 
containing trypsin (T) or proteinase K (PK) before being solubilized 
and the soluble fractions were analyzed by SDS-PAGVautoradiog- 
raphy. 
done by incubating aliquots of virus in PBS containing 
0.002 M PMSF, 1% aprotinin, and O-4% 2-ME for 15 
min at 37”, pelleting the virus through a 25% sucrose 
cushion by centrifugation at 50,000 gfor 60 min, resus- 
pending the samples in medium, and assaying for in- 
fectivity. The results, seen in Table 1, indicate that 
while the infectivity of all three preparations was 
affected, protease-treated BV was more sensitive than 
TABLE 1 
COMPARATIVE EFFECTS OF 2-ME ON THE INFECTIVITY OF PROTEASE- 
TREATED AND UNTREATED BV 
BV treatments 
%2-ME’ PBS 
0 5.906 (0) 
1.0 5.88 (0.02) 
2.0 5.70 (0.20) 
4.0 2.48 (3.42) 
Trypsin 
6.30 (0) 
5.78 (0.52) 
3.30 (3.00) 
3.16(3.14) 
Proteinase K 
6.41 (0) 
6.10(0.31) 
4.71 (2.24) 
2.70 (3.71) 
‘Virus was incubated with 2-ME at the indicated concentrations 
for 15 min at 37’ before being assayed for infectivity. 
b The mean titer (PFU/ml) is expressed as the base 10 logarithm. 
Standard deviations were all within 0.5 loglo units of the mean. 
c The number in parentheses is the decrease in titer from the 0% 
2-ME value. 
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FIG. 3. Neutralization of BV and protease-treated BV with AcV, and 
anti-BV. BV, trypsin-treated BV, and proteinase K-treated BV were 
incubated with medium, medium containing AcV,, or medium con- 
taining anti-BV for 1 hr at 37” before being assayed for infectivity. 
AC!‘, 
BV. Both trypsin and proteinase K-treated virus lost sig- 
nificant infectivity (over 1 OO-fold) after exposure to 2% 
2-ME, while the PBS-treated control preparation lost 
minimal infectivity. The infectivity of all three prepara- 
tions decreased over 1 OOO-fold after exposure to 4% 
2-ME, however. In an effort to determine whether this 
loss of infectivity was due to dissociation of 64K or its 
cleavage fragments from the virus, [35S]methionine-la- 
beled BV and protease-treated BV were analyzed by 
SDS-PAGE and autoradiography following exposure to 
4% 2-ME for 15 min at 37”. Neither 64K nor its proteo- 
lytic cleavage fragments were dissociated from the vi- 
rus (Fig. 1, lanes marked ME). These results indicate 
that while neither 64K nor its cleavage fragments ap- 
pear to be thiol linked to virus, disulfide bonds are im- 
portant in the conformation of their biologically active 
domain(s). The increased sensitivity of the retained 
cleavage fragments to 2-ME could be explained if the 
fragments contained fewer disulfide bonds than the 
uncleaved protein, and/or if protease cleavage caused 
the disulfide bonds to become more accessible. 
In order to determine whether protease-treated BV 
could be neutralized by AcV, and anti-BV, neutraliza- 
tion experiments were performed by incubating pro- 
tease-treated and untreated BV for 1 hr at 37” in either 
a 1:42 dilution (in medium) of rabbit antiserum to BV 
(anti-BV) (13) or 0.12 pg/ml medium of affinity-purified 
AcV, monoclonal antibody (17). Following the incuba- 
tion period, the infectivity of the samples was deter- 
mined. The results were that BV was significantly neu- 
tralized by both antibody preparations, but protease- 
treated BV was neutralized only by antiserum to BV 
(Fig. 3). To ensure that the lack of AcV, neutralizing ac- 
tivity for protease-treated BV was not due to antibody 
degradation by residual protease, we tested for the 
presence of active AcV, in the AcV,-protease-treated 
BV neutralization samples. After incubation, the sam- 
ples were centrifuged at 100,000 g to remove most of 
the protease-treated BV, then the supernatant fluids 
were tested for residual infectivity and for their ability to 
neutralize freshly added BV. The BV neutralizing ca- 
pacity was found to be intact; it reduced the infectivity 
of the BV-spiked preparations by 2.7 orders of magni- 
tude (data not shown). 
To determine whether the protease-generated frag- 
ments of 64K reacted with AcV, and anti-BV, immuno- 
precipitation experiments were done as described pre- 
viously-except this time we used a higher concentra- 
tion of PMSF (0.004 nJI). The results (Fig. 4) indicated 
that while anti-BV recognized 64K as well as all the 
cleavage fragments generated by both trypsin and pro- 
teinase K, AcV, recognized only the uncleaved 64K. 
The AcV,-reactive epitope apparently was destroyed 
by the protease treatments, which accounts for the 
lack of AcV, neutralizing activity against protease- 
treated BV. The fact that particles lacking the AcV,-re- 
active epitope were no less infectious than normal par- 
ticles indicates that even though antibody binding of 
the epitope neutralizes the virus, the epitope itself is 
not important for infection. 
Previous studies have shown that populations of BV 
saturated with AcV, are reduced in titer lOOO- to 
1 O,OOO-fold, but that complete neutralization does not 
occur (18). Studies have shown that the residual infec- 
tivity of AcV,-saturated BV, unlike BV, is not sensitive 
BV TREATMENTS 
FIG. 4. lmmunoprecipitation of 64K and its cleavage fragments by 
AcV, and anti-BV. Solubilized (S) [36S]methionine-labeled 64K or pro- 
tease-generated cleavage fragments of 64K were incubated with 
anti-BV (A, antiserum) or AcV, (M. monoclonal), immunoprecipitated 
with protein A-Sepharose Cl-48 beads, and analyzed by SDS-PAGE 
and autoradiography. 
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FIG. 5. Chloroquine-sensitivity of BV and protease-treated BV in 
IPLB-SF-21 (SF) and TN-368 (Tn) cells. The infectivity of BV and pro- 
tease-treated BV was compared in the presence and absence of 1 
mM chloroquine. 
to inhibition by lipophilic amines. These studies re- 
sulted in the hypothesis that the function of the 64K 
protein is to allow efficient entry of BV by adsorptive 
endocytosis. Because proteolytic cleavage renders BV 
nonneutralizable by AcV, but does not reduce infectiv- 
ity, it occurred to us that such a cleavage of 64K might 
be a normal part of the infection process after adsorp- 
tion of BV to susceptible host cells. Natural proteolytic 
cleavage of surface glycoproteins has been shown for 
several enveloped viruses, including paramyxo, myxo, 
and coronaviruses (3, 7, 8, 10-72). This cleavage fre- 
quently plays an important role in viral infectivity and 
host specificity. If such a cleavage takes place in the 
course of AcMNPV BV infection, we reasoned that it 
might take place in and be dependent on the acidic en- 
vironment of endocytic vesicles, We were interested, 
therefore, in determining whether protease-treated BV 
infectivitiy was sensitive to inhibition by chloroquine, a 
lipophilic amine that prevents the acidification of endo- 
somes. This was done by performing infectivity assays 
in the presence of 1 mhllchloroquine as described pre- 
viously (17). The results in Fig. 5 show that infection of 
both IPLB-SF-21 and TN-368 cells by protease-treated 
BV is sensitive to chloroquine. Cleavage of 64K does 
not release BV from the requirement of functionally en- 
tering cells via acidic endosomes. If protease cleavage 
does take place in a natural infection and is dependent 
on an acidic environment, it is not the only event impor- 
tant to BV infectivitiy that is pH-sensitive and takes 
place in endosomes. 
The infectivitiy of some of the viruses requiring pro- 
teolytic cleavage has been shown to be suppressable 
by the presence of protease inhibitors during infection 
(3, 19,20). As part of a search for evidence of a required 
natural proteolytic cleavage of 64K during infection, we 
tested the effects of various protease inhibitors on viral 
infectivity. We incubated cells for 2 hr before and 
throughout infection with various concentrations of 
leupeptin, aprotinin, pepstatin, N-tosyl-i-phenylalanine 
chloromethyl ketone (TPCK), and 6-amino-n-hexanoic 
acid but found no evidence that any one of them ad- 
versely affected BV infectivity (data not shown). 
Another approach taken in search for a role for natu- 
ral proteolytic cleavage was to look for an increase in 
infectivity of protease-treated over that of untreated BV 
in alternate, semipermissive cell lines, with the hypoth- 
esis that their low susceptibility could be due to the 
lack of necessary proteolytic enzymes. In a previous 
study we documented the relative susceptibilities of 
several cell lines to AcMNPV BV infection (16). Two of 
the least susceptible were MRRL-CH and IPLB-SD- 
652, cell lines derived from Manduca sexta and Lyman- 
via &oar, respectively. The infectivities of protease- 
treated and untreated BV were compared using these 
two cell lines with the result that protease treatment 
did not induce greater infectivity, but rather slightly less 
(data not shown). 
Although the approaches taken to generate evi- 
dence that protease cleavage of 64K might be a natural 
and necessary part of infection were preliminary and by 
no means exhaustive, the lack of such evidence led 
to an alternate hypothesis that we might be observing 
resistance to functional inactivation by proteases in- 
stead of activation. We reasoned it was possible that 
BV could be exposed to proteases during natural infec- 
tion in the insect hemocoel, and if so, had to be some- 
what functionally resistant to proteolysis in order to re- 
main infectious. 
To test this possibility, hemolymph was removed 
from several fourth instar T. ni larvae infected for 48 
and 96 hr. The larvae were each infected by per OS in- 
jection of 1 ng of polyhedra-derived AcMNPV. This 
dose represents about 666 LDsO doses (6). The hemo- 
lymph was diluted in medium and the titer of the virus 
and its sensitivity to neutralization by AcV, and anti-BV 
was determined as before (Fig. 3). The results were 
that hemolymph-derived virus from both 48- and 96 hr- 
infected larvae was neutralized by both AcV, and anti- 
BV (data not shown). These results indicated that the 
virus was not subjected to severe proteolysis in the 
hemolymph even by 96 hr postinfection when obvious 
signs of disease were apparent. 
Our search for a biological explanation for the ob- 
served functional resistance of the 64K protein to pro- 
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teolytic degradation was unsuccessful. Nevertheless 
we found that the biological activity of 64K was con- 
tained in fragments about half the size of the native pro- 
tein. The fragments were glycosylated and located 
proximal to the virus surface relative to the portion that 
is degraded by proteases. We found that disulfide 
bonds play an important role in maintaining the confor- 
mation of biologically important domains of both native 
and truncated 64K, but do not serve to link them to the 
virion. Finally, we found that the epitope reactive to 
neutralizing antibody AcV, does not play an important 
role in BV infectivity. 
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